APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Immuno Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oncology Immuno Drug Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchOncology Immuno Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Immuno Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Oncology Immuno Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Immuno Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Immuno Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Oncology Immuno Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oncology Immuno Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oncology Immuno Drug market include Bristol-Myers Squibb, Dendreon Pharmaceuticals, Gilead Sciences Inc., Merck & Co, Sanofi S.A., AstraZeneca, Roche AG, Merck KGaA and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oncology Immuno Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Immuno Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Immuno Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oncology Immuno Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncology Immuno Drug Segment by Company

Bristol-Myers Squibb

Dendreon Pharmaceuticals

Gilead Sciences Inc.

Merck & Co

Sanofi S.A.

AstraZeneca

Roche AG

Merck KGaA

Novartis

Oncology Immuno Drug Segment by Type

CAR-T Cell Therapy

Cancer Vaccines

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Oncology Immuno Drug Segment by Application

Hospitals

Drugstores

Others

Oncology Immuno Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Oncology Immuno Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oncology Immuno Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology Immuno Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology Immuno Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Immuno Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Immuno Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Immuno Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oncology Immuno Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Immuno Drug industry.

Chapter 3: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oncology Immuno Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oncology Immuno Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology Immuno Drug Industry Trends Table 2. Oncology Immuno Drug Industry Drivers Table 3. Oncology Immuno Drug Industry Opportunities and Challenges Table 4. Oncology Immuno Drug Industry Restraints Table 5. Global Oncology Immuno Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology Immuno Drug Revenue Share by Company (2021-2026) Table 7. Global Oncology Immuno Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Oncology Immuno Drug Sales Volume Share by Company (2021-2026) Table 9. Global Oncology Immuno Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Oncology Immuno Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oncology Immuno Drug Key Company Manufacturing Base & Headquarters Table 12. Global Oncology Immuno Drug Company, Product Type & Application Table 13. Global Oncology Immuno Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oncology Immuno Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CAR-T Cell Therapy Table 18. Significant Companies of Cancer Vaccines Table 19. Significant Companies of Cytokine-Based Immunotherapy Table 20. Significant Companies of Immune Checkpoint Inhibitors Table 21. Significant Companies of Other Table 22. Global Oncology Immuno Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Oncology Immuno Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Oncology Immuno Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Oncology Immuno Drug Sales Volume Share by Type (2021-2026) Table 26. Global Oncology Immuno Drug Sales Volume Share by Type (2027-2032) Table 27. Global Oncology Immuno Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oncology Immuno Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Oncology Immuno Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Oncology Immuno Drug Sales Value Share by Type (2021-2026) Table 31. Global Oncology Immuno Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospitals Table 33. Significant Companies of Drugstores Table 34. Significant Companies of Others Table 35. Global Oncology Immuno Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Oncology Immuno Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Oncology Immuno Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Oncology Immuno Drug Sales Volume Share by Application (2021-2026) Table 39. Global Oncology Immuno Drug Sales Volume Share by Application (2027-2032) Table 40. Global Oncology Immuno Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Oncology Immuno Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Oncology Immuno Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Oncology Immuno Drug Sales Value Share by Application (2021-2026) Table 44. Global Oncology Immuno Drug Sales Value Share by Application (2027-2032) Table 45. Global Oncology Immuno Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Oncology Immuno Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Oncology Immuno Drug Sales Market Share by Region (2021-2026) Table 48. Global Oncology Immuno Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Oncology Immuno Drug Sales Market Share by Region (2027-2032) Table 50. Global Oncology Immuno Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Oncology Immuno Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Oncology Immuno Drug Sales Value Share by Region (2021-2026) Table 53. Global Oncology Immuno Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Oncology Immuno Drug Sales Value Share by Region (2027-2032) Table 55. Global Oncology Immuno Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Oncology Immuno Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Oncology Immuno Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Oncology Immuno Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Oncology Immuno Drug Sales Market Share by Country (2021-2026) Table 61. Global Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Oncology Immuno Drug Sales Market Share by Country (2027-2032) Table 63. Global Oncology Immuno Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Oncology Immuno Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Oncology Immuno Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Oncology Immuno Drug Sales Value Market Share by Country (2027-2032) Table 67. Bristol-Myers Squibb Company Information Table 68. Bristol-Myers Squibb Business Overview Table 69. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio Table 71. Bristol-Myers Squibb Recent Development Table 72. Dendreon Pharmaceuticals Company Information Table 73. Dendreon Pharmaceuticals Business Overview Table 74. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio Table 76. Dendreon Pharmaceuticals Recent Development Table 77. Gilead Sciences Inc. Company Information Table 78. Gilead Sciences Inc. Business Overview Table 79. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio Table 81. Gilead Sciences Inc. Recent Development Table 82. Merck & Co Company Information Table 83. Merck & Co Business Overview Table 84. Merck & Co Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Merck & Co Oncology Immuno Drug Product Portfolio Table 86. Merck & Co Recent Development Table 87. Sanofi S.A. Company Information Table 88. Sanofi S.A. Business Overview Table 89. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Sanofi S.A. Oncology Immuno Drug Product Portfolio Table 91. Sanofi S.A. Recent Development Table 92. AstraZeneca Company Information Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. AstraZeneca Oncology Immuno Drug Product Portfolio Table 96. AstraZeneca Recent Development Table 97. Roche AG Company Information Table 98. Roche AG Business Overview Table 99. Roche AG Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Roche AG Oncology Immuno Drug Product Portfolio Table 101. Roche AG Recent Development Table 102. Merck KGaA Company Information Table 103. Merck KGaA Business Overview Table 104. Merck KGaA Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Merck KGaA Oncology Immuno Drug Product Portfolio Table 106. Merck KGaA Recent Development Table 107. Novartis Company Information Table 108. Novartis Business Overview Table 109. Novartis Oncology Immuno Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Novartis Oncology Immuno Drug Product Portfolio Table 111. Novartis Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Oncology Immuno Drug Distributors List Table 115. Oncology Immuno Drug Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Oncology Immuno Drug Product Image Figure 2. Global Oncology Immuno Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Immuno Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oncology Immuno Drug Sales (2021-2032) & (K Units) Figure 5. Global Oncology Immuno Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Oncology Immuno Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CAR-T Cell Therapy Image Figure 10. Cancer Vaccines Image Figure 11. Cytokine-Based Immunotherapy Image Figure 12. Immune Checkpoint Inhibitors Image Figure 13. Other Image Figure 14. Global Oncology Immuno Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Oncology Immuno Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Oncology Immuno Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Oncology Immuno Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Oncology Immuno Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Oncology Immuno Drug Sales Value Share by Type (2021-2032) Figure 20. Hospitals Image Figure 21. Drugstores Image Figure 22. Others Image Figure 23. Global Oncology Immuno Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Oncology Immuno Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Oncology Immuno Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Oncology Immuno Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Oncology Immuno Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Oncology Immuno Drug Sales Value Share by Application (2021-2032) Figure 29. Global Oncology Immuno Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Oncology Immuno Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Oncology Immuno Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Oncology Immuno Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Oncology Immuno Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Oncology Immuno Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Oncology Immuno Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Oncology Immuno Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Oncology Immuno Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Oncology Immuno Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Oncology Immuno Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Oncology Immuno Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Oncology Immuno Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Oncology Immuno Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Oncology Immuno Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Oncology Immuno Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Oncology Immuno Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Dendreon Pharmaceuticals
  • Gilead Sciences Inc.
  • Merck & Co
  • Sanofi S.A.
  • AstraZeneca
  • Roche AG
  • Merck KGaA
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oncology Immuno Drug Sales Value (2021-2032)
  4. 1.2.2 Global Oncology Immuno Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Oncology Immuno Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oncology Immuno Drug Market Dynamics
  1. 2.1 Oncology Immuno Drug Industry Trends
  2. 2.2 Oncology Immuno Drug Industry Drivers
  3. 2.3 Oncology Immuno Drug Industry Opportunities and Challenges
  4. 2.4 Oncology Immuno Drug Industry Restraints
3 Oncology Immuno Drug Market by Company
  1. 3.1 Global Oncology Immuno Drug Company Revenue Ranking in 2025
  2. 3.2 Global Oncology Immuno Drug Revenue by Company (2021-2026)
  3. 3.3 Global Oncology Immuno Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Oncology Immuno Drug Average Price by Company (2021-2026)
  5. 3.5 Global Oncology Immuno Drug Company Ranking (2024-2026)
  6. 3.6 Global Oncology Immuno Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Oncology Immuno Drug Company Product Type and Application
  8. 3.8 Global Oncology Immuno Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oncology Immuno Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oncology Immuno Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oncology Immuno Drug Market by Type
  1. 4.1 Oncology Immuno Drug Type Introduction
  2. 4.1.1 CAR-T Cell Therapy
  3. 4.1.2 Cancer Vaccines
  4. 4.1.3 Cytokine-Based Immunotherapy
  5. 4.1.4 Immune Checkpoint Inhibitors
  6. 4.1.5 Other
  7. 4.2 Global Oncology Immuno Drug Sales Volume by Type
  8. 4.2.1 Global Oncology Immuno Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Oncology Immuno Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Oncology Immuno Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Oncology Immuno Drug Sales Value by Type
  12. 4.3.1 Global Oncology Immuno Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Oncology Immuno Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Oncology Immuno Drug Sales Value Share by Type (2021-2032)
5 Oncology Immuno Drug Market by Application
  1. 5.1 Oncology Immuno Drug Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Oncology Immuno Drug Sales Volume by Application
  6. 5.2.1 Global Oncology Immuno Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oncology Immuno Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Oncology Immuno Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Oncology Immuno Drug Sales Value by Application
  10. 5.3.1 Global Oncology Immuno Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oncology Immuno Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Oncology Immuno Drug Sales Value Share by Application (2021-2032)
6 Oncology Immuno Drug Regional Sales and Value Analysis
  1. 6.1 Global Oncology Immuno Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology Immuno Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Oncology Immuno Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Oncology Immuno Drug Sales by Region (2027-2032)
  5. 6.3 Global Oncology Immuno Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oncology Immuno Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oncology Immuno Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oncology Immuno Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Oncology Immuno Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oncology Immuno Drug Sales Value (2021-2032)
  12. 6.6.2 North America Oncology Immuno Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oncology Immuno Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Oncology Immuno Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oncology Immuno Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oncology Immuno Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oncology Immuno Drug Sales Value (2021-2032)
  21. 6.9.2 South America Oncology Immuno Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oncology Immuno Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oncology Immuno Drug Sales Value Share by Country, 2025 VS 2032
7 Oncology Immuno Drug Country-level Sales and Value Analysis
  1. 7.1 Global Oncology Immuno Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology Immuno Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oncology Immuno Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Oncology Immuno Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Oncology Immuno Drug Sales by Country (2027-2032)
  6. 7.4 Global Oncology Immuno Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oncology Immuno Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oncology Immuno Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oncology Immuno Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oncology Immuno Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oncology Immuno Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Dendreon Pharmaceuticals
  8. 8.2.1 Dendreon Pharmaceuticals Company Information
  9. 8.2.2 Dendreon Pharmaceuticals Business Overview
  10. 8.2.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio
  12. 8.2.5 Dendreon Pharmaceuticals Recent Developments
  13. 8.3 Gilead Sciences Inc.
  14. 8.3.1 Gilead Sciences Inc. Company Information
  15. 8.3.2 Gilead Sciences Inc. Business Overview
  16. 8.3.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio
  18. 8.3.5 Gilead Sciences Inc. Recent Developments
  19. 8.4 Merck & Co
  20. 8.4.1 Merck & Co Company Information
  21. 8.4.2 Merck & Co Business Overview
  22. 8.4.3 Merck & Co Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co Oncology Immuno Drug Product Portfolio
  24. 8.4.5 Merck & Co Recent Developments
  25. 8.5 Sanofi S.A.
  26. 8.5.1 Sanofi S.A. Company Information
  27. 8.5.2 Sanofi S.A. Business Overview
  28. 8.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi S.A. Oncology Immuno Drug Product Portfolio
  30. 8.5.5 Sanofi S.A. Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Oncology Immuno Drug Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Roche AG
  38. 8.7.1 Roche AG Company Information
  39. 8.7.2 Roche AG Business Overview
  40. 8.7.3 Roche AG Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Roche AG Oncology Immuno Drug Product Portfolio
  42. 8.7.5 Roche AG Recent Developments
  43. 8.8 Merck KGaA
  44. 8.8.1 Merck KGaA Company Information
  45. 8.8.2 Merck KGaA Business Overview
  46. 8.8.3 Merck KGaA Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Merck KGaA Oncology Immuno Drug Product Portfolio
  48. 8.8.5 Merck KGaA Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Oncology Immuno Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Oncology Immuno Drug Product Portfolio
  54. 8.9.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oncology Immuno Drug Value Chain Analysis
  2. 9.1.1 Oncology Immuno Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oncology Immuno Drug Sales Mode & Process
  6. 9.2 Oncology Immuno Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oncology Immuno Drug Distributors
  9. 9.2.3 Oncology Immuno Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst